Basic information Safety Supplier Related

SB 239063

Basic information Safety Supplier Related

SB 239063 Basic information

Product Name:
SB 239063
Synonyms:
  • SB 239063
  • TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(4-FLUOROPHENYL)-5-(2-METHOXYPYRIDIMIDIN-4-YL)IMIDAZOLE
  • TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(4-FLUOROPHENYL)-5-(2-METHOXYPYRIMIDIN-4-YL) IMIDAZOLE
  • TRANS-1-(4-HYDROXYCYCLOHEXYL)-4-(FLUOROPHENYL)-5-(2-METHOXYPYRIMIDIN-4-YL) IMIDAZOLE
  • TRANS-4-[4-(4-FLUOROPHENYL)-5-(2-METHOXY-4-PYRIMIDINYL)-1H-IMIDAZOL-1-YL]CYCLOHEXANOL
  • Cyclohexanol, 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]-, trans-
  • SB 239063 - CAS 798558-40-4 - Calbiochem
  • CS-402
CAS:
193551-21-2
MF:
C20H21FN4O2
MW:
368.4
Product Categories:
  • Aromatics
  • Heterocycles
  • Protein Kinase Inhibitors and Activators
Mol File:
193551-21-2.mol
More
Less

SB 239063 Chemical Properties

Melting point:
206-207.2 °C
storage temp. 
2-8°C
solubility 
DMSO: 11 mg/mL
form 
White solid
color 
white
InChIKey
ZQUSFAUAYSEREK-WKILWMFISA-N
More
Less

Safety Information

Safety Statements 
22-24/25
WGK Germany 
3
RTECS 
GV9458000
HS Code 
2933599590

MSDS

More
Less

SB 239063 Usage And Synthesis

Uses

SB239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen-glucose-deprived hippocampal slice cultures. A protein kinase inhibitor

Uses

SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.

Definition

ChEBI: A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.

General Description

SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.

Hazard

A poison by ingestion.

Biological Activity

Potent and selective p38 MAP kinase inhibitor (IC 50 = 44 nM for p38a). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580 (4-[5-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-1H-i midazol-4-yl]pyridine and 4-[5-(4-Fluorophenyl)-2-[4-(methylsulphonyl)phenyl]-1H- imidazol-4-yl]pyridine hydrochloride ). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo .

Biochem/physiol Actions

Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.

in vitro

in oxygen-glucose-deprived hippocampal slice cultures, treatment with 20 μm and 100 μm sb239063 significantly reduced the levels of the pro-inflammatory cytokine il-1β and reduced cell death after oxygen-glucose deprivation and strikingly diminished microglia activation[2].

in vivo

oral administration of 3–30 mg/kg sb 239063 given twice a day dose-dependently inhibited airway neutrophil infiltration and interleukin (il)-6 levels 48 h after lipopolysaccharide (lps) inhalation [1]. in a bleomycin-induced pulmonary fibrosis model rats, sb 239063 treatment (2.4 or 4.8 mg/day via osmotic pump) significantly inhibited bleomycin-induced right ventricular hypertrophy (indicative of secondary pulmonary hypertension) and increased in lung hydroxyproline synthesis (indicative of collagen synthesis and fibrosis) (1). in conscious guinea pigs, administration of sb 239063 (10 or 30 mg/kg p.o.) showed approximately 50% inhibition of oa-induced pulmonary eosinophil influx, measured by bal 24 h after antigen(1). orally administration of sb 239063 (30 mg/kg) attenuated il-6 bronchoalveolar lavage fluid concentrations (> 90% inhibition) and mmp-9 activity (64% inhibition) measured 6 h after lps exposure. in guinea pig cultured alveolar macrophages, sb 239063 inhibited lps-induced il-6 production with ic50 of 362 nm. in lipopolysaccharide-stimulated human peripheral blood monocytes, sb 239063 inhibited il-1 and tnf-α production with an ic50 of 0.12 and 0.35 μm, respectively(1).

storage

Desiccate at +4°C

References

[1] underwood d c, osborn r r, bochnowicz s, et al. sb 239063, a p38 mapk inhibitor, reduces neutrophilia, inflammatory cytokines, mmp-9, and fibrosis in lung[j]. american journal of physiology-lung cellular and molecular physiology, 2000, 279(5): l895-l902.
[2] strassburger m, braun h, reymann k g. anti-inflammatory treatment with the p38 mitogen-activated protein kinase inhibitor sb239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen–glucose-deprived hippocampal slice cultures[j]. european journal of pharmacology, 2008, 592(1): 55-61.

SB 239063Supplier

Hangzhou ChangCun Biotechnology Co., Ltd. Gold
Tel
0571-; 13567100326
Email
158848739@qq.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
Chemsky (shanghai) International Co.,Ltd
Tel
021-50135380
Email
shchemsky@sina.com